ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interleukins (IL)"

  • Abstract Number: L13 • 2019 ACR/ARP Annual Meeting

    Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Philip J. Mease1, Proton Rahman 2, Alice B. Gottlieb 3, Elizabeth Hsia 4, Alexa Kollmeier 5, Xie Xu 6, Ramanand Subramanian 5, Prasheen Agarwal 5, Shihong Sheng 5, Bei Zhou 5, Désirée van der Heijde 7 and Iain McInnes 8, 1Swedish Medical Center and University of Washington, Seattle, Washington, 2Memorial University of Newfoundland, Newfoundland, Canada, 3Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, 4Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, 5Janssen Research & Development, LLC, Spring House, Pennsylvania, 6Janssen Research & Development, LLC, Spring House, 7Leiden University Medical Center, Leiden, Netherlands, 8Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
  • Abstract Number: L21 • 2019 ACR/ARP Annual Meeting

    Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study

    Atul Deodhar1, Ricardo Blanco 2, Eva Dokoupilova 3, Marleen van de Sande 4, Stephen Hall 5, Anna Wiksten 6, Brian Porter 7, Hanno Richards 6, Sibylle Haemmerle 6 and Jürgen Braun 8, 1Oregon Health & Science University, Portland, OR, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Brno, Czech Republic, 4Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam UMC /University of Amsterdam, Amsterdam, Netherlands, 5Monash University, Melbourne, Australia, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

    Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…
  • Abstract Number: 1524 • 2019 ACR/ARP Annual Meeting

    Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study

    Alice Gottlieb 1, Ana-Maria Orbai 2, Rocco Ballerini 3, Richard C. Chou 4, Stephen Rozzo 3, Alan Mendelsohn3 and Luis R. Espinoza 5, 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 4University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, 5Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA

    Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved by the FDA to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo-controlled, phase 2b…
  • Abstract Number: 1525 • 2019 ACR/ARP Annual Meeting

    Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial

    Christopher Ritchlin 1, Vibeke Strand 2, Rocco Ballerini 3, Richard C. Chou 4, Stephen Rozzo 3, Alan Mendelsohn3 and Arthur Kavanaugh 5, 1Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, 2Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, Palo Alto, CA, 3Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 4University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, 5University of California, San Diego School of Medicine, La Jolla, CA

    Background/Purpose: Tildrakizumab (TIL) is an anti–interleukin-23p19 monoclonal antibody approved by the FDA for treatment of moderate-to-severe plaque psoriasis1,2 and is under investigation for treatment of…
  • Abstract Number: 1526 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study

    Wendy Cantrell 1, Patricia Lee 2, Emil Tanghetti 3, Alan Mendelsohn4, Jeff Parno 4, Stephen Rozzo 4 and Wilson Liao 5, 1Department of Dermatology, University of Alabama Birmingham, Birmingham, AL, USA; Dermatology at the Whitaker Clinic, Birmingham, AL, USA, Birmingham, AL, 2Center for Clinical Studies, Webster, TX, USA, Webster, TX, 3Center for Dermatology and Laser Surgery, Sacramento, CA, USA, Sacramento, CA, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 5Department of Dermatology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA

    Background/Purpose: We assessed residual plaque psoriasis in patients successfully treated with anti–interleukin-23p19 monoclonal antibody tildrakizumab (TIL) who interrupted treatment, relapsed, and were retreated vs continuously…
  • Abstract Number: 1527 • 2019 ACR/ARP Annual Meeting

    Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program

    Holly Glover 1, Kristine Kucera 2, Alan Mendelsohn3, Jeff Parno 3, Stephen Rozzo 3, Frank Ferritto 4 and Renata Block 5, 1Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA, McKinney, TX, 2North Texas Dermatology, Richardson, TX, USA, Richardson, TX, 3Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 4Polley Dermatology, Wilson, NC, USA, Wilson, NC, 5Pinski Dermatology & Cosmetic Surgery, Chicago, IL, USA, Chicago, IL

    Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody with demonstrated efficacy for the treatment of chronic plaque psoriasis in a phase 2b (P05495 [NCT01225731])…
  • Abstract Number: 1554 • 2019 ACR/ARP Annual Meeting

    Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study

    Philip Mease1, Robert B.M. Landewé 2, Proton Rahman 3, Hasan Tahir 4, Atul Singhal 5, Elke Böttcher 6, Sandra Navarra 7, Aimee Readie 8, Shephard Mpofu 9, Evie Maria Delicha 9, Luminita Pricop 8 and Désirée van der Heijde 10, 1Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 2Amsterdam University Medical Center, Amsterdam, Netherlands, 3Memorial University, Newfoundland, NL, Canada, 4Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, 5Southwest Rheumatology, Dallas, TX, 6Rheumazentrum Favoriten, Vienna, Austria, 7University of Santo Tomas Hospital, Manila, Philippines, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Novartis Pharma AG, Basel, Switzerland, 10Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Secukinumab (SEC) provided sustained efficacy, inhibition of radiographic progression, and stable safety profile over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA)…
  • Abstract Number: 1768 • 2019 ACR/ARP Annual Meeting

    A First-in-class Selective and Potent IRAK4 Degrader Demonstrates Robust in Vitro and in Vivo Inhibition of TLR/IL-1R Activation and Inflammation

    Veronica Campbell1, Joseph Kelleher 1, Jesse Chen 1, Jared Gollob 2, Nan Ji 2, Christine Klaus 2, Christine Loh 2, Michelle mayo 2, Alice McDonald 2, Haojing Rong 2, Scott Rusin 2, Kirti Sharma 2, Matt Weiss 2, Karen Yuan 2, Duncan Walker 2, Xiaozhang Zheng 2, Anthony Slavin 2 and Nello Mainolfi 2, 1Kymera Therapeutics, cambridge, MA, 2Kymera Therapeutics, Cambridge

    Background/Purpose: IL-1R/TLR activation plays a central role in the pathophysiology of multiple autoimmune and inflammatory diseases driven by the IL-1 family of cytokines and by…
  • Abstract Number: 1776 • 2019 ACR/ARP Annual Meeting

    Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study

    Dongze WU1, Priscilla Wong 1, Steven H.M. Lam 1, Isaac T. Cheng 1, Edmund K. Li 1, Ling Qin 1 and Lai-Shan Tam 1, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Biologic agents targeting cytokines including TNF-α, IL-12p70 and IL-17 have been proven to be very effective in treating psoriatic arthritis (PsA).  Nonetheless, whether these…
  • Abstract Number: 1821 • 2019 ACR/ARP Annual Meeting

    Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain

    Ana-Maria Orbai 1, Rocco Ballerini 2, Richard C. Chou 3, Stephen Rozzo 2, Alan Mendelsohn2 and Luis R. Espinoza 4, 1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 3University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, 4Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA

    Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo (PBO)-controlled, phase 2b study (NCT02980692)…
  • Abstract Number: 1976 • 2019 ACR/ARP Annual Meeting

    Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5

    Mahamudul Haque1, Madeline McDougal 1, Anil Singh 1 and Salahuddin Ahmed 2, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, SPOKANE, WA, 2Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA

    Background/Purpose: Osteoarthritis (OA) is a chronic degenerative joint disease caused by synovial inflammation and cartilage degradation primarily driven by interleukin-1beta (IL-1β). Studies suggest that TNF-stimulated…
  • Abstract Number: 2145 • 2019 ACR/ARP Annual Meeting

    Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials

    Diamant Thaçi 1, Kristian Reich 2, Jo Lydie Lambert 3, Lars Iversen 4, Andrea Peserico 5, Ignasi Pau-Charles 6, Andrew Blauvelt7 and Christopher Griffiths 8, 1Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, Lübeck, Germany, 2University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Skinflammation®, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany, Hamburg, Germany, 3Department of Dermatology, Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, 4Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 5Clinica Dermatologica, Department of Medicine-DIMED University of Padua, Padua, Italy, Padua, Italy, 6Almirall R&D, Barcelona, Spain, Barcelona, Spain, 7Oregon Medical Research Center, Portland, OR, USA, Portland, OR, 8Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom

    Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to evaluate…
  • Abstract Number: 111 • 2019 ACR/ARP Annual Meeting

    The Transcription Factor STAT3 Regulates Pathogenic Th17 Responses in Autoimmune Disease via Noncanonical Roles

    Catherine Poholek1, Itay Raphael 2 and Mandy McGeachy 2, 1UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: The Th17 lineage of CD4 T cells drives autoimmune diseases such as RA, SLE, IBD, and MS. The JAK2/STAT3 signaling pathway is required for…
  • Abstract Number: 2856 • 2019 ACR/ARP Annual Meeting

    Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register

    Burkhard Moeller1, Eleftherios Papagiannoulis 2, Lisa Christ 3, Adrian Ciurea 4, Thomas Hugle 5, Ruediger B. Mueller 6, Michael J. Nissen 7, Almut Scherer 8, Godehard Scholz 3, Peter M. Villiger 1 and Nikhil Yawalkar 3, 1University Hospital Bern, Bern, Switzerland, 2SCQM Zurich, Zurich, Switzerland, 3Inselspital-University Hospital Bern, Bern, Switzerland, 4University Hospital Zürich, Zürich, Switzerland, 5University Hospital Lausanne, Lausanne, Switzerland, 6Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, 7University Hospital Geneva, Geneva, Switzerland, 8SCQM Foundation, Zürich, Switzerland

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) were the first approved biological disease modifying antirheumatic drugs (bDMARDs) for psoriatic arthritis (PsA). IL-12/23 and IL-17-specific antibodies provide…
  • Abstract Number: 112 • 2019 ACR/ARP Annual Meeting

    Impact of Interleukin-9 on the Immune Suppressive Functions of Regulatory T Cells in Rheumatoid Arthritis

    Sushmita Chakraborty 1, Ranjan Gupta 2, Rinkee Kumari 1 and Dipendra Kumar Mitra1, 1All India Institute of Medical Sciences, Delhi, Delhi, India, 2All India Institute of Medical Sciences, New Delhi, India

    Background/Purpose: An important component of the immune tolerance is regulatory T cells (Tregs), which prevents autoimmunity and restrains inflammatory reactions. In Rheumatoid Arthritis (RA), there…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology